Antipneumococcal Activities of GAR-936 (a New Glycylcycline) Compared to Those of Nine Other Agents against Penicillin-Susceptible and -Resistant Pneumococci

AUTOR(ES)

Hoellman, Dianne B.

FONTE

American Society for Microbiology

RESUMO

GAR-936, a new glycylcycline, had lower MICs (≤0.016 to 0.125 μg/ml) for 201 penicillin- and tetracycline-susceptible and -resistant pneumococcal strains than tetracycline (≤0.06 to 128 μg/ml), minocycline (≤0.06 to 16.0 μg/ml), or doxycycline (≤0.06 to 32.0 μg/ml). GAR-936 was also bactericidal against 11 of 12 strains tested at the MIC after 24 h, with significant kill rates at earlier time points.

Documentos Relacionados

• Postantibiotic effect of sanfetrinem compared with those of six other agents against 12 penicillin-susceptible and -resistant pneumococci.
• Activities of oral and parenteral agents against penicillin-susceptible and -resistant pneumococci.
• Comparative activities of LY 333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci.
• Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.
• Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci.